Drug Profile
VTP 100
Alternative Names: Influenza virus vaccine - Barinthus Biotherapeutics; MVA-M1+NP; MVA-NP+M1; Universal influenza vaccine - Barinthus Biotherapeutics; VTP-100Latest Information Update: 12 Dec 2023
Price :
$50
*
At a glance
- Originator Vaccitech
- Developer Barinthus Biotherapeutics
- Class Influenza virus DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza A virus infections
Most Recent Events
- 25 Jul 2022 No development reported - Phase-II for Influenza A virus infections (Prevention, In adults) in Belgium (IM)
- 15 May 2019 Vaccitech in-licenses ProBioGen’s proprietary technology platform based on the AGE1.CR® duck retina cell line
- 18 Mar 2019 Phase-II clinical trials in Influenza virus infections (In the elderly, Prevention, In adults, Adjunctive treatment) in Australia (IM, Injection) (NCT03880474)